112 related articles for article (PubMed ID: 8898177)
1. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
Rose PG; Blessing JA; Lewandowski GS; Creasman WT; Webster KD
Gynecol Oncol; 1996 Oct; 63(1):101-4. PubMed ID: 8898177
[TBL] [Abstract][Full Text] [Related]
2. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
3. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
Rose PG; Blessing JA; Soper JT; Barter JF
Gynecol Oncol; 1998 Aug; 70(2):267-71. PubMed ID: 9740703
[TBL] [Abstract][Full Text] [Related]
4. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
Sutton GP; Blessing JA; DeMars LR; Moore D; Burke TW; Grendys EC
Gynecol Oncol; 1996 Oct; 63(1):25-7. PubMed ID: 8898163
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group study.
Poplin EA; Liu PY; Delmore JE; Wilczynski S; Moore DF; Potkul RK; Fine BA; Hannigan EV; Alberts DS
Gynecol Oncol; 1999 Sep; 74(3):432-5. PubMed ID: 10479505
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W
Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
Pierga JY; Diéras V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P
Gynecol Oncol; 1997 Aug; 66(2):246-9. PubMed ID: 9264570
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix.
Morris M; Brader KR; Burke TW; Levenback CF; Gershenson DM
Gynecol Oncol; 1998 Aug; 70(2):215-8. PubMed ID: 9740693
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Rose PG; Brunetto VL; VanLe L; Bell J; Walker JL; Lee RB
Gynecol Oncol; 2000 Aug; 78(2):212-6. PubMed ID: 10926805
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of altretamine for advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Rose PG; Blessing JA; Arseneau J
Gynecol Oncol; 1996 Jul; 62(1):100-2. PubMed ID: 8690279
[TBL] [Abstract][Full Text] [Related]
11. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study.
Look KY; Blessing JA; Valea FA; McGehee R; Manetta A; Webster KD; Andersen WA
Gynecol Oncol; 1997 Dec; 67(3):255-8. PubMed ID: 9441772
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
15. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
16. Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.
Rose PG; Markman M; Bell JG; Fusco NL
Gynecol Oncol; 2006 Aug; 102(2):236-9. PubMed ID: 16412499
[TBL] [Abstract][Full Text] [Related]
17. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
[TBL] [Abstract][Full Text] [Related]
18. Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group.
Moore DH; Blessing JA; Dunton C; Buller RE; Reid GC
Gynecol Oncol; 1999 Dec; 75(3):473-5. PubMed ID: 10600310
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study.
Gridelli C; Rossi A; Scognamiglio F; Guida C; Fiore F; Gatani T; Scoppa G; Pergola M
Anticancer Res; 1997; 17(6D):4755-8. PubMed ID: 9494602
[TBL] [Abstract][Full Text] [Related]
20. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Rose PG; Blessing JA; Mayer AR; Homesley HD
J Clin Oncol; 1998 Feb; 16(2):405-10. PubMed ID: 9469322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
